Biomarkers are critical tools in drug discovery, development, and diagnostic phases with many different types of markers that help you make more informed and faster decisions. They serve as surrogates for assessing the activity of candidate therapeutics, and can be indispensable tools for validating targets, proving the mechanism of action, and predicting therapeutic efficacy, as well as alerting for potential toxicity.
However, the process of identifying and validating new disease-related and pharmacodynamic biomarkers is still difficult. Biomarker identification is a multi-step and iterative process beginning early in the drug discovery stage, which helps build a strong biomarker testing strategy across all phases of development. Our biomarker services can help you translate them to the clinic and beyond while greatly accelerating candidate development and decreasing timelines.
Optimal biomarker assays create a knowledge framework for confident decision making to help minimize risk. With techniques like genomics, transcriptomics, proteomics, cytometrics, and metabolomics, companies may use many different approaches to discover and develop biomarkers.
Supporting the selection of biomarkers from early identification through to the clinical
Our comprehensive global portfolio of biomarker services covers key toxicological indications and a range of therapeutic areas, including oncology, inflammation, immunology, infectious disease, ocular disease, metabolism, and disease of the cardiovascular, renal, respiratory, and central nervous systems. From early discovery through clinical support, our biomarker services can help you identify novel biomarkers or select, validate, qualify, and apply known biomarkers to validate a target, prove a mechanism of action, predict therapeutic efficacy, or identify potential toxicity. Through our CLIA certification, we can also develop novel biomarkers for use in diagnostic testing, post market patient safety monitoring, and companion diagnostic testing.
Our knowledge and expertise allows us to assist with the discovery of biologically and scientifically relevant biomarkers, as well as the measurement and interpretation of their changes within the test system relating them to the drug development program. Scientific excellence is ensured by a synergy between experts in multiple areas, adding value to the studies.
CORE BIOMARKER SERVICES
- Biomarker Identification and Assay Development
- Behavioral Assessments
- Fluid and Tissue Based Assays
- Physiological and Functional Assessments
- Imaging Capabilities
- Diagnostic Testing
Searchable Biomarker Database
Streamline your search for the right biomarkers for your project with our biomarker database, a centralized quick-reference repository. Select your criteria or browse biomarkers by therapeutic area, toxicological indication and species.
Frequently Asked Questions (FAQs) for Biomarker Services
How can biomarker testing add value to my program?
Biomarker testing serves as a surrogate for assessing the activity of candidate therapeutics, and can be indispensable tools for validating targets, proving the mechanism of action and predicting therapeutic efficacy, as well as alerting for potential toxicity. The ability to develop biomarkers in animal models and then translate them to the clinic can greatly accelerate candidate development and decrease timelines.
Which therapeutic areas do you offer biomarker analysis for?
We offer a comprehensive range of biomarker services in key therapeutic areas and toxicological indications. From early discovery stages to clinical support, our scientists have the expertise to relate biomarkers to every stage of a drug development program. We employ multidisciplinary teams of experts in oncology, inflammation, immunology, infectious disease, ocular disease, metabolism, and diseases of the cardiovascular, renal, respiratory, and central nervous systems.
- How can I access your biomarker services?